Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)
1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. 2. Description: Amplification or overexpression of MYC oncoproteins, master regulator of cancers, are observed in over 28% common cancer types. The Technology is a novel aurora kinase inhibitor which was …
